Study on Clozapines Immune Effects in Parkinsons Disease Patients with Psychosis

What this Trial Is About

Researchers are studying the effects of clozapine, a second-generation antipsychotic drug used to treat psychosis in Parkinsons disease PD patients. The study focuses on clozapine-related immunodeficiency, which may cause decreased immune function and increased infection risk over time. This research aims to explore changes in immune system markers in PD patients treated with clozapine, as current data mainly involve psychiatric patients with schizophrenia. Participants will undergo blood tests to measure serum immunoglobulin levels and lymphocyte subpopulations B, T, NK cells at the start of clozapine treatment, six months later, and again at one year. The study involves regular monitoring of blood counts weekly for the first 18 weeks and then monthly while on treatment, continuing for four weeks after stopping clozapine. Additional immunological assays are added during these scheduled blood tests. Participants will be monitored through blood tests and clinical assessments during the study. Researchers will evaluate changes in serum IgG levels after six months as the primary outcome. The study will also track immune cell populations over time. Safety monitoring includes regular blood count checks to detect potential risks like neutropenia. The total follow-up extends at least one year after treatment initiation, allowing thorough observation of immune changes.

Clozapine-related Immunodeficiency in Parkinsons Disease